Fund Evaluator:
Invesco Nasdaq Biotechnology ETF (IBBQ)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$0.000
NAV (as of )
$0.00
Minimum Initial
0.19% A
Expense Ratio
$76 Mil
Assets
Open
Status
na
12b-1 Fee
0.80%
TTM Yield
0.00%
Max Load
17%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 62.8% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 62.6% | Fidelity Advisor Biotechnology I (FBTIX) |
| 56.2% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 53.5% | Fidelity Select Biotechnology (FBIOX) |
| 49.5% | Fidelity Select Pharmaceuticals Port (FPHAX) |
Data as of 7/31/2026
-1.7% D
1-Mo Return
10.2% D
3-Mo Return
13.3% B
YTD Return
45.4% B
1-Yr Return
16.8% A
3-Yr Return
5.4% B
5-Yr Return
0.84 B
Category Risk Index
1.38
Total Risk Index
Fund Details
Fund Family
Invesco
Inception Date
6/11/2021
Share Class Type
Equity Investment Style
Mid-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
NASDAQ Composite TR USD: 100%
Additional Fund Details
Invesco Nasdaq Biotechnology ETF Overview
IBBQ Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| IBBQ Return (NAV) | -1.7% | 10.2% | 45.4% | 16.8% | 5.4% | na |
| IBBQ Grade | D | D | B | A | B | na |
| +/- Category | -1.3% | -0.5% | 11.5% | 6.2% | 0.4% | na |
| Health Avg | -0.4% | 10.7% | 33.9% | 10.7% | 5.0% | 9.3% |
| IBBQ Tax Cost Ratio | na | na | 0.4% | 0.3% | 0.3% | na |
IBBQ Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| IBBQ Return (NAV) | 13.3% | 33.4% | -0.6% | 4.5% | -10.2% | na | na | na | na | na | na |
| IBBQ Grade | B | A | D | B | C | na | na | na | na | na | na |
| +/- Category | 6.2% | 12.8% | -3.1% | -1.1% | -0.8% | na | na | na | na | na | na |
| Health Avg | 7.1% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 16.9% |
| Total Risk Index: | 1.38 - Above Average |
| Category Risk Index: | 0.84 - Average |
| Category Risk Grade: | B (40% Rank) |
| Beta: | 0.62 |
| R-Squared: | 22% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.8% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | |
| Total Assets: | $76 Mil |
| Fund Total Assets: | $ 76 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 17% |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 5.1 years | |||
| Average Tenure: 5.1 years | |||
| Managers (Year): Hubbard Peter (2021), Jeanette Michael (2021), Doshi Pratik (2021) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 258 |
| % in Top 10 Holdings: | 42.3% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 5.4% |
Portfolio Allocation |
|
| Domestic Stock: | 94.5% |
| Foreign Stock: | 5.4% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Fund Family: | Invesco |
| Phone Number: | 800-983-0903 |
| Website: | www.invescopowershares.com |
| Status: | Open |
| Inception Date: | June 11, 2021 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.19% ( Rating : Low ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Invesco Nasdaq Biotechnology ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.